Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.04 -0.10 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Bristol-Myers Squibb (BMY) Q3 2021 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers Q3 Earnings In-line With Expectations, Raises Lower End Of FY21 Adjusted EPS Outlook
Bristol Myers Squibb & Co (NYSE: BMY) has posted Q3 revenues of $11.6 billion, an increase of 10%, in line with the consensus estimate of $11.58 billion. ... 
Via Benzinga
Bristol Myers Inches Up As Cancer Drugs Help Drive Narrow Quarterly Beat
Bristol Myers credited cancer drugs Opdivo and Revlimid for helping drive its growth. 
Via Investor's Business Daily
Cyber Currency
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
Aurinia Rockets — Again — On Rumored Bristol Marriage; Could Others Make A Pass?
Aurinia stock hit another record Monday on Bristol's rumored takeover. 
Via Investor's Business Daily
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today
The biotech is reportedly in buyout talks with Bristol Myers Squibb. 
Via The Motley Fool
Aurinia Pharma Stock Pops On Reports Of Looming Bristol Myers Takeover
Bristol is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying before it was halted. 
Via Investor's Business Daily
Thursday Market Coverage
US jobless benefit applicants last week hit a pandemic low of 290,000, below the estimate of 300,000. 
Via Talk Markets
Clorox and Church & Dwight versus Amgen and Bristol-Myers Squibb
Base your stock investment decisions on fundamental values rather than short-term price activity. 
Via Talk Markets
Ventyx Jumps Over 20% Today After NASDAQ Debut
Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket. This... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
Exposures Product Safety
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
The Secret To Successful Investing In Biotech
Have you ever had a stock jump 30%, 50% or 100% in one day? 
Via Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to... 
Via Talk Markets
Europe's Unicorns
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
Death Cross Looms Over Bristol-Myers Squibb Investors
If history is any guide, there may be trouble ahead for shares of Bristol-Myers Squibb(NYSE:BMY). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
MINDCURE's "Desire Project" uses MDMA to Treat Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Photo by Visual Stories || Micheile on Unsplash Mental health is becoming a major concern globally in the wake of the Covid-19 pandemic after historically being an issue... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Evotec Expands Neuroscience Collaboration with Bristol Myers
Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related:... 
Via Benzinga
Markets Boosted
Good news helped stock prices. 
Via Talk Markets
Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study
Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative... 
Via Benzinga
Best Pharmaceutical Stocks To Buy In 2021
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars. 
Via Talk Markets
Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane
Former Tilray Exec Steven Yoo Named Texas Original Compassionate Cultivation's New CFO Texas medical cannabis provider,&n... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
2 Ridiculously Cheap Growth Stocks to Buy
Though these companies have recorded solid financials of late, investors are overlooking them. 
Via The Motley Fool
Bristol Myers Squibb: Should You Buy the Dip?
Short-term volatility can be a patient, long-term investor's best friend. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.